Transgene (XPAR:TNG) Other Gross PPE : €26.15 Mil (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Transgene Other Gross PPE?

Transgene's Other Gross PPE for the quarter that ended in Dec. 2023 was €26.15 Mil.

Transgene's quarterly Other Gross PPE declined from Dec. 2022 (€27.47 Mil) to Jun. 2023 (€11.08 Mil) but then increased from Jun. 2023 (€11.08 Mil) to Dec. 2023 (€26.15 Mil).

Transgene's annual Other Gross PPE increased from Dec. 2021 (€12.33 Mil) to Dec. 2022 (€27.47 Mil) but then declined from Dec. 2022 (€27.47 Mil) to Dec. 2023 (€26.15 Mil).

Transgene Other Gross PPE Historical Data

The historical data trend for Transgene's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Other Gross PPE Chart

Transgene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

11.06

12.20

12.33

27.47

26.15

Transgene Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Gross PPE	Get a 7-Day Free Trial															12.33	12.22	27.47	11.08	26.15

Transgene Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Transgene (XPAR:TNG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

TGNA:Germany

Address

400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines